Nervomatrix back pain device WINS FDA nod

Targetech Innovation Center company nervomatrix Ltd., developed by the auto focus on lower back pain relief neurostimulation device, has received US Food and Drug Administration (FDA) approval to market the device in the United States.

The device to check behind, locate points If the resistance is low compared to their nearby and stimulates the nerves with a gentle electrical current that reduces pain, according to the company's tests.

Nervomatrix's technology is based on acupuncture-encouraging the identification of the nerve endings on the map. "We've dropped after acupuncture map. We don t use this word, even the CEO of the company's "we are very proud to announce Nervomatrix Ori" Globes "Kanner told today. "We have developed their own empiric method to learn, which refers to contribute."

Acupuncture is not accepted by conventional medicine, and its encouragement to comply with any of the items on the map of the classic Anatomy corresponds to the map. Researchers have shown that acupuncture has some positive effect on the amount has grown in recent years.

Kanner said: "our work, we found that the various books, acupuncture configuration does not need to match, and there was no penalty to a patient who came to us. In contrast, the resistance to improve their ability to use the correct nerve endings. Classic acupuncture map-handling and requires expertise, according to doctors. In contrast, when compared to the other, in particular, for the measurement of the resistance, you can do anything a technician at. "

Back to Nervomatrix have a patent shall expire at the end of the scanner and the Locator, which takes into account the surrounding area as compared to their relative resistance of nerve. "We've noticed that when a pain weakens, electrical tension equalizes at the various points," said Kanner's personal page on Stardoll. "In the future, it may be possible to use the progress of the data processing. We may consider whether the person has actually been suffering the pain, that it is important to prevent insurance companies from fraud. "

Nervomatrix runs it first trial Bnei Zion hospital in Haifa. 85% of patients reported an improvement in their condition, but there was no control group. The company's next step is to run a clinical trial at the University of New York, as it begins the two substances, the doctor patient centers in New York City, with its products.

5. January 2011 Globes [online]-Israel business news www.globes-online.com-in-publication

Copyright Globes Publisher Itonut (1983) Ltd. in 2011

View the original article here